NCT00757341

Study Evaluating The Mass Balance And Metabolic Disposition Of SKI-606

An Open-Label, Single-Dose Study of the Mass Balance and Metabolic Disposition of Orally Administered [14C]-Labeled Bosutinib in Healthy Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 6 (estimated)
• Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer · Industry
• Sex: Male
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

This study will assess the mass balance, metabolic disposition, and identification of metabolites following single oral administration of \[14C\]-SKI-606 in healthy male subjects.

Conditions

• Healthy Subjects

Interventions

Type	Name	Description
DRUG	SKI-606

Timeline

• Start date: 2008-12-01
• Primary completion: 2008-12-01
• Completion: 2008-12-01
• First posted: 2008-09-23
• Last updated: 2009-04-27

Locations

1 site across 1 country: United States